@article{Polvere2022, 
author = {Immacolata Polvere and Serena Voccola and Gaetano Cardinale and Maurizio Fumi and Francesca Aquila and Alfredina Parrella and Jessica Raffaella Madera and Romania Stilo and Pasquale Vito and Tiziana Zotti},
title = {A peptide-based assay discriminates individual antibody response to SARS-CoV-2},
year = {2022},
journal = {Genes & Diseases},
volume = {9},
number = {1},
pages = {275-281},
keywords = {Antibodies, Assay, COVID-19, ELISA, Peptides, SARS-Cov-2},
url = {https://www.sciopen.com/article/10.1016/j.gendis.2021.01.008},
doi = {10.1016/j.gendis.2021.01.008},
abstract = {SARS-CoV-2 virus is responsible for the current worldwide coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. Understanding the antibody response to SARS-CoV-2 is crucial for the development of vaccines, therapeutics and public health interventions. However, lack of consistency in methods used to monitor antibody response to SARS-CoV-2 leaves some uncertainty in our fine understanding of the human antibody response mounted following SARS-CoV-2 infection. We developed a peptide-based enzyme-linked immunosorbent assay (ELISA) by selecting 7 synthetic peptides from the spike, membrane, and nucleocapsid protein sequences of SARS-CoV-2, which effectively detects the antibody response mounted by all COVID-19 convalescent tested. Strikingly, the assay shows a profound difference in antibody response among individual subjects, which may have a significant impact on disease severity. Together, our results define an efficient and specific serological assay to consistently measure the antibody response following SARS-CoV-2 infection, as well as help the design of vaccine and therapeuticals for prevention and treatment of COVID-19.}
}